Vor Biopharma Inc

NASDAQ VOR

Download Data

Vor Biopharma Inc Gross Profit Margin for the year ending December 31, 2023

Vor Biopharma Inc Gross Profit Margin is NA for the year ending December 31, 2023. Gross Profit Margin represents the percentage of revenue that represents gross profit, indicating the efficiency of a company's production and pricing.
NASDAQ: VOR

Vor Biopharma Inc

CEO Dr. Robert Ang M.B.A., M.D., MBBS
IPO Date Feb. 5, 2021
Location United States
Headquarters 100 Cambridgepark Drive, Cambridge, MA, United States, 02140
Employees 168
Sector Healthcare
Industry Biotechnology
Description

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Similar companies

GRCL

Gracell Biotechnologies Inc.

NA

NA

THRX

Theseus Pharmaceuticals Inc

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

EWTX

Edgewise Therapeutics Inc

NA

NA

ACET

Adicet Bio Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email